Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development." …
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 22, 2024 Australian Biotech
Latest Video
New Stories
-
The Week in Review Podcast - 3 May
May 3, 2024 - - Podcast -
New data shows significant increase in the number of pharmacies supplying naloxone
May 3, 2024 - - Latest News -
CSL Seqirus secures local rights to new adrenaline nasal spray
May 3, 2024 - - Latest News -
Industry applauds funding commitment for National One Stop Shop for clinical trials
May 3, 2024 - - Latest News -
Access should not be redefined as including access via a clinical trial
May 3, 2024 - - Latest News -
Another reform process fails - how many times does this need to happen?
May 2, 2024 - - Latest News -
New coalition established to advocate for action on radiation therapy
May 2, 2024 - - Latest News